AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7030855 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK + Verapamil (50 mg continuous drip)
Number of subjects: 100
Study 7030855 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK + Digoxin (0.25 mg b.i.d.)
Number of subjects: 100
Study 7030855 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK + Verapamil + Digoxin
Number of subjects: 100
Study 6705802 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Intensive Care Unit (MICU) manned by paramedics 24/7 and part-time by CCU nurses, dispatched to all suspected emergencies.
Number of subjects: 181
Study 6705802 — intervention group
Group type: COMPARATOR
Intervention: Mobile Coronary Care Unit (MCCU) manned by two CCU nurses and two ambulance drivers, operational on workdays from 08:00 to 17:00.
Number of subjects: 181
Study 29519378 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 1811
Study 29519378 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 1811
Study 26884592 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 × 5 Gy and three cycles of FOLFOX4 (group A)
Number of subjects: 515
Study 26884592 — intervention group
Group type: COMPARATOR
Intervention: 50.4 Gy in 28 fractions combined with two 5‐day cycles of bolus 5‐Fu 325 mg/m(2)/day and leucovorin 20 mg/m(2)/day during the first and fifth week of irradiation along with five infusions of oxaliplatin 50 mg/m(2) once weekly (group B)
Number of subjects: 515
Study 25225081 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 0
Study 25225081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23171211 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids
Number of subjects: 0
Study 23171211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20860447 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative wound infiltration with 150 mL ropivacaine (2 mg/mL), 1 mL ketorolac (30 mg/mL), and 0.5 mL epinephrine (1 mg/mL) combined with intraarticular infusion (4 mL/h) of 190 mL ropivacaine (2 mg/mL) plus 2 mL ketorolac (30 mg/mL) (group A)
Number of subjects: 40
Study 20860447 — intervention group
Group type: COMPARATOR
Intervention: Epidural infusion (4 mL/h) of 192 mL ropivacaine (2 mg/mL) combined with 6 intravenous administrations of 0.5 mL ketorolac (30 mg/mL) for 48 h postoperatively (group E)
Number of subjects: 40
Study 18647201 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD
Number of subjects: 38
Study 18647201 — intervention group
Group type: EXPERIMENTAL
Intervention: GTR
Number of subjects: 38
Study 18647201 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD+GTR
Number of subjects: 38
Study 18647201 — intervention group
Group type: COMPARATOR
Intervention: OFD
Number of subjects: 38
Study 16042229 — intervention group
Group type: EXPERIMENTAL
Intervention: MSQoL-54
Number of subjects: 215
Study 12425407 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate (Peridex)
Number of subjects: 561
Study 12425407 — intervention group
Group type: COMPARATOR
Intervention: Listerine (control)
Number of subjects: 561
Study 10529932 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0% dorzolamide/0.5% timolol fixed combination (COSOPT)
Number of subjects: 190
Study 10529932 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol plus 2.0% pilocarpine
Number of subjects: 190
Study 7724111 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sulindac (200 mg, once orally every 12 hours for 7 days)
Number of subjects: 69
Study 7724111 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once orally every 12 hours for 7 days)
Number of subjects: 69
Study 1924952 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (250 mg/day)
Number of subjects: 179
Study 1924952 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 179
Study 6259918 — intervention group
Group type: EXPERIMENTAL
Intervention: C-terminal octapeptide of cholecystokinin (4 ng/kg/min)
Number of subjects: 12
Study 6259918 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 12
Study 30564928 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha lipoic acid (ALA), oral, twice daily for 6 weeks
Number of subjects: 102
Study 30564928 — intervention group
Group type: COMPARATOR
Intervention: Placebo, twice daily for 6 weeks
Number of subjects: 102
Study 28941056 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text messaging intervention
Number of subjects: 314
Study 28941056 — intervention group
Group type: COMPARATOR
Intervention: No SMS text messaging (Control)
Number of subjects: 314
Study 24753120 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) + self-help
Number of subjects: 45
Study 24753120 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation + self-help
Number of subjects: 45
Study 23806258 — intervention group
Group type: EXPERIMENTAL
Intervention: AAA simulation course with dedicated vascular surgery faculty instruction (Group B, n = 10)
Number of subjects: 18
Study 23806258 — intervention group
Group type: COMPARATOR
Intervention: AAA simulation course with surgical skills lab coordinator instruction (Group A, n = 8)
Number of subjects: 18
Study 23806258 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 18
Study 21093861 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum PAPP‐A (≥4mIU/L)
Number of subjects: 4243
Study 19940476 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrofluoric acid (HF) 0.2%, pH 2.0
Number of subjects: 103
Study 19940476 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous fluoride (SnF(2)) 0.78%, pH 2.9
Number of subjects: 103
Study 18007129 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 18007129 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive pill
Number of subjects: 0
Study 18007129 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise
Number of subjects: 0
Study 15207837 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sildenafil
Number of subjects: 282
Study 15207837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study 12640223 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (AMI)
Number of subjects: 94
Study 12640223 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (PAROX)
Number of subjects: 94
Study 10082152 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral glibenclamide
Number of subjects: 26
Study 10082152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 7560608 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine
Number of subjects: 50
Study 7560608 — intervention group
Group type: COMPARATOR
Intervention: Sotalol
Number of subjects: 50
Study 1778860 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg daily for neonates, 1000 mg daily for adults)
Number of subjects: 55
Study 1778860 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin (50 mg daily for neonates, 300 mg daily for adults)
Number of subjects: 55
Study 6753547 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (4 to 8 mg, orally administered)
Number of subjects: 8
Study 6753547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31891790 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised communication
Number of subjects: 16
Study 31891790 — intervention group
Group type: COMPARATOR
Intervention: Closed-loop communication
Number of subjects: 16
Study 29095417 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based multimedia patient engagement program (Emmi Solutions)
Number of subjects: 0
Study 26614573 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent involvement in cognitive behavioral therapy (CBT)
Number of subjects: 24
Study 26614573 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent involvement in therapy
Number of subjects: 24
Study 26614573 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist involvement in therapy
Number of subjects: 24
Study 26614573 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent and therapist perspectives
Number of subjects: 24
Study 24651665 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced perfusion
Number of subjects: 59
Study 22699670 — intervention group
Group type: EXPERIMENTAL
Intervention: Interceptive Orthodontics (IO) followed by Observation (OBS)
Number of subjects: 170
Study 22699670 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive Orthodontics (CO)
Number of subjects: 170
Study 20186874 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 'ds+hrHPV': high‐risk HPV facts and de‐stigmatising components
Number of subjects: 294
Study 20186874 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 'lr+hrHPV': low‐risk and high‐risk HPVs facts
Number of subjects: 294
Study 20186874 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 'hrHPV': high‐risk HPV facts only
Number of subjects: 294
Study 20186874 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 294
Study 18063209 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain 1% lidocaine
Number of subjects: 40
Study 18063209 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine diluted with saline
Number of subjects: 40
Study 15741830 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) 500 microg
Number of subjects: 13
Study 15741830 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (placebo)
Number of subjects: 13
Study 15741830 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 13
Study 11999609 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion (2.5, 5.0, and 7.5 microg kg(‐1) min(‐1))
Number of subjects: 9
Study 11999609 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (150 microg intravenously) given during dopamine infusion (7.5 microg kg(‐1) min(‐1))
Number of subjects: 9
Study 11999609 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (150 microg intravenously) given 15 min before dopamine infusion
Number of subjects: 9
Study 9431333 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical direct reports encouraging the consideration of peritoneal dialysis
Number of subjects: 152
Study 9431333 — intervention group
Group type: COMPARATOR
Intervention: Usual information without clinical direct reports
Number of subjects: 152
Study 8208677 — intervention group
Group type: EXPERIMENTAL
Intervention: GenHevac B vaccine (20 micrograms)
Number of subjects: 120
Study 8208677 — intervention group
Group type: COMPARATOR
Intervention: Hevac B vaccine (5 micrograms)
Number of subjects: 120
Study 2684077 — intervention group
Group type: EXPERIMENTAL
Intervention: methylprednisolone acetate (20 mg) intrabursal injection and oral naproxen (1 g/d for 10 days)
Number of subjects: 42
Study 2684077 — intervention group
Group type: EXPERIMENTAL
Intervention: methylprednisolone acetate (20 mg) intrabursal injection and oral placebo for 10 days
Number of subjects: 42
Study 2684077 — intervention group
Group type: COMPARATOR
Intervention: oral naproxen (1 g/d for 10 days)
Number of subjects: 42
Study 2684077 — intervention group
Group type: COMPARATOR
Intervention: oral placebo for 10 days
Number of subjects: 42
Study 4875006 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin (2 g orally daily)
Number of subjects: 5
Study 4875006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 4875006 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin
Number of subjects: 5
Study 30113425 — intervention group
Group type: COMPARATOR
Intervention: 3 interruptions
Number of subjects: 70
Study 30113425 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 interruptions
Number of subjects: 70
Study 30698725 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate (CHO) 0 g protein
Number of subjects: 48
Study 30698725 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk protein (MILK) 20 g
Number of subjects: 48
Study 30698725 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (WHEY) 20 g
Number of subjects: 48
Study 30698725 — intervention group
Group type: EXPERIMENTAL
Intervention: Micellar casein protein (CASEIN) 20 g
Number of subjects: 48
Study 30698725 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein (MILK, WHEY, CASEIN pooled)
Number of subjects: 48
Study 29349988 — intervention group
Group type: COMPARATOR
Intervention: Patient-Controlled Intravenous Analgesia (PCIA) with controlled instillation of sufentanil
Number of subjects: 40
Study 29349988 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia including continuous femoral nerve block, local injection of knee joint, and buprenorphine patches
Number of subjects: 40
Study 26479485 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual-based multimodal treatment (MT)
Number of subjects: 112
Study 26479485 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 112
Study 23307488 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week aerobic training program (3 sessions/week, 30-40 min at 55-65% peak heart rate)
Number of subjects: 20
Study 23307488 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 22124031 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS + Occupational Therapy (OT) for 5 consecutive days (30 minutes each session)
Number of subjects: 0
Study 22124031 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS + Occupational Therapy (OT)
Number of subjects: 0
Study 18325821 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport (40, 80, and 120 units/eye)
Number of subjects: 0
Study 18325821 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport (80 units/eye)
Number of subjects: 0
Study 18325821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16536811 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week interval treatment with pulsed-dye laser (PDL)
Number of subjects: 15
Study 16536811 — intervention group
Group type: COMPARATOR
Intervention: 6-week interval treatment with pulsed-dye laser (PDL)
Number of subjects: 15
Study 14514628 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid infusion
Number of subjects: 21
Study 15374046 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip protector (pads) worn by residents for 9 months
Number of subjects: 71
Study 15374046 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hip protector)
Number of subjects: 71
Study 15374046 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip protector (pads) worn by residents
Number of subjects: 71
Study 9221571 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin (group A)
Number of subjects: 47
Study 9221571 — intervention group
Group type: COMPARATOR
Intervention: Human insulin (group B)
Number of subjects: 47
Study 7963115 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 40
Study 7963115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3623783 — intervention group
Group type: EXPERIMENTAL
Intervention: HR combined with RPE
Number of subjects: 24
Study 3623783 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study 3623783 — intervention group
Group type: EXPERIMENTAL
Intervention: HR alone
Number of subjects: 24
Study 3623783 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 24
Study 29723235 — intervention group
Group type: EXPERIMENTAL
Intervention: Anma therapy (AMT)
Number of subjects: 40
Study 29723235 — intervention group
Group type: COMPARATOR
Intervention: No Anma therapy (no-AMT)
Number of subjects: 40
Study 27157890 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-BM22
Number of subjects: 204
Study 26407218 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted lemon juice (G0)
Number of subjects: 630
Study 26407218 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-fat milk (G1)
Number of subjects: 630
Study 26407218 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control group, G2)
Number of subjects: 630
Study 23616159 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent syncope (≥5/lifetime)
Number of subjects: 431
Study 23616159 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthostatic intolerance
Number of subjects: 431
Study 23616159 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine diagnosis
Number of subjects: 431
Study 23616159 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent syncope and orthostatic intolerance
Number of subjects: 431
Study 21786434 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol pretreatment (200 mg/day for 7 days)
Number of subjects: 120
Study 21786434 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cilostazol pretreatment)
Number of subjects: 120
Study 19368659 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI after ingestion of 800 mL meal
Number of subjects: 16
Study 19368659 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI after ingestion of 200 mL meal
Number of subjects: 16
Study 19368659 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath test (BT) after ingestion of 200 mL meal
Number of subjects: 16
Study 19368659 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath test (BT) after ingestion of 800 mL meal
Number of subjects: 16
Study 19368659 — intervention group
Group type: EXPERIMENTAL
Intervention: Barostat measurements
Number of subjects: 16
Study 17077429 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual music therapy plus standard care
Number of subjects: 81
Study 17077429 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 81
Study 15080785 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day
Number of subjects: 30
Study 15080785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11189687 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening intervention
Number of subjects: 74000
Study 11189687 — intervention group
Group type: COMPARATOR
Intervention: Nonscreened control
Number of subjects: 74000
Study 9065193 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml of 0.4% chlorhexidine
Number of subjects: 947
Study 9065193 — intervention group
Group type: COMPARATOR
Intervention: 20 ml of sterile water (placebo)
Number of subjects: 947
Study 8055498 — intervention group
Group type: EXPERIMENTAL
Intervention: Counter-rotational powered brush
Number of subjects: 0
Study 8055498 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods
Number of subjects: 0
Study 3578969 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine-assisted intubation (SAI)
Number of subjects: 52
Study 3578969 — intervention group
Group type: COMPARATOR
Intervention: Blind nasotracheal intubation (BNI)
Number of subjects: 52
Study 29277353 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV 4-dose vial (with preservative)
Number of subjects: 320
Study 29277353 — intervention group
Group type: COMPARATOR
Intervention: PHiD-CV 1-dose vial (preservative-free)
Number of subjects: 320
Study 29277353 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PHiD-CV 4-dose and 1-dose)
Number of subjects: 320
Study 26527245 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-rated personal recovery
Number of subjects: 0
Study 26527245 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-rated clinical recovery
Number of subjects: 0
Study 26527245 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff-rated clinical recovery
Number of subjects: 0
Study 26527245 — intervention group
Group type: EXPERIMENTAL
Intervention: HHI, CANSAS-P, and HoNOS
Number of subjects: 0
Study 24797544 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel ocular bandage (HOB) applied to the corneal incision at the end of the surgery
Number of subjects: 30
Study 24797544 — intervention group
Group type: COMPARATOR
Intervention: No hydrogel ocular bandage (Control group)
Number of subjects: 30
Study 22682536 — intervention group
Group type: COMPARATOR
Intervention: ULLIN
Number of subjects: 413
Study 22682536 — intervention group
Group type: COMPARATOR
Intervention: TLLIN+IRS
Number of subjects: 413
Study 22682536 — intervention group
Group type: COMPARATOR
Intervention: ULLIN+CTPS
Number of subjects: 413
Study 22682536 — intervention group
Group type: EXPERIMENTAL
Intervention: TLLIN
Number of subjects: 413
Study 20306128 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy radiation therapy (PMRT)
Number of subjects: 1818
Study 20306128 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy alone
Number of subjects: 1818
Study 18356694 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus tirofiban infusion administered together during inclusion (n = 10)
Number of subjects: 17
Study 18356694 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel administered at inclusion and followed 2 hours after by tirofiban (n = 7)
Number of subjects: 17
Study 18356694 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus tirofiban infusion (group A)
Number of subjects: 17
Study 18356694 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel administered at inclusion and followed 2 hours after by tirofiban (group B)
Number of subjects: 17
Study 15978308 — intervention group
Group type: COMPARATOR
Intervention: Control (treatment A): intact tablet with 120 mL water
Number of subjects: 10
Study 15978308 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment B: crushed tablet mixed with 4 oz applesauce
Number of subjects: 10
Study 15978308 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment C: crushed tablet mixed with 120 mL of a common ENF
Number of subjects: 10
Study 14613023 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg once daily)
Number of subjects: 0
Study 14613023 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (20 mg once daily)
Number of subjects: 0
Study 14613023 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Anastrozole plus Tamoxifen
Number of subjects: 0
Study 10356087 — intervention group
Group type: EXPERIMENTAL
Intervention: 500-microgram phylloquinone tablet
Number of subjects: 11
Study 10356087 — intervention group
Group type: COMPARATOR
Intervention: 150 g of raw spinach
Number of subjects: 11
Study 10356087 — intervention group
Group type: COMPARATOR
Intervention: 50 g of spinach
Number of subjects: 11